[go: up one dir, main page]

CY1111470T1 - Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α - Google Patents

Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α

Info

Publication number
CY1111470T1
CY1111470T1 CY20111100475T CY111100475T CY1111470T1 CY 1111470 T1 CY1111470 T1 CY 1111470T1 CY 20111100475 T CY20111100475 T CY 20111100475T CY 111100475 T CY111100475 T CY 111100475T CY 1111470 T1 CY1111470 T1 CY 1111470T1
Authority
CY
Cyprus
Prior art keywords
pharmaceutical compositions
compositions containing
polymorph
flyverserin
new pharmaceutical
Prior art date
Application number
CY20111100475T
Other languages
English (en)
Inventor
Thomas Friedl
Guido Bernhard Edmund Radtke
Original Assignee
Boehringer Ingelheim Pharma Gmbh & Co. Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma Gmbh & Co. Kg filed Critical Boehringer Ingelheim Pharma Gmbh & Co. Kg
Publication of CY1111470T1 publication Critical patent/CY1111470T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Η εφεύρεση αναφέρεται σε στοματικές φαρμακευτικές συνθέσεις που περιέχουν φλιβανσερίνη πολύμορφη Α, μεθόδους για την παρασκευή τους και τη χρήση τους ως φάρμακα.
CY20111100475T 2002-05-22 2011-05-17 Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α CY1111470T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02011224 2002-05-22
EP03730069A EP1511489B1 (en) 2002-05-22 2003-05-19 New pharmaceutical compositions containing flibanserin polymorph a

Publications (1)

Publication Number Publication Date
CY1111470T1 true CY1111470T1 (el) 2015-08-05

Family

ID=29433081

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111100475T CY1111470T1 (el) 2002-05-22 2011-05-17 Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α

Country Status (25)

Country Link
EP (1) EP1511489B1 (el)
JP (1) JP3919788B2 (el)
KR (1) KR101054237B1 (el)
CN (3) CN101002780A (el)
AT (1) ATE499939T1 (el)
BR (1) BRPI0311189B8 (el)
CA (1) CA2483597C (el)
CY (1) CY1111470T1 (el)
DE (1) DE60336225D1 (el)
DK (1) DK1511489T3 (el)
EA (1) EA007185B1 (el)
EC (1) ECSP045493A (el)
ES (1) ES2361994T3 (el)
HR (1) HRP20041092B1 (el)
IL (1) IL164440A0 (el)
ME (1) MEP55308A (el)
MX (1) MXPA04011487A (el)
NO (1) NO329414B1 (el)
NZ (1) NZ537253A (el)
PL (1) PL211062B1 (el)
RS (1) RS51718B (el)
SI (1) SI1511489T1 (el)
UA (1) UA80135C2 (el)
WO (1) WO2003097058A1 (el)
ZA (1) ZA200408151B (el)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7183410B2 (en) 2001-08-02 2007-02-27 Bidachem S.P.A. Stable polymorph of flibanserin
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US20050239798A1 (en) * 2004-04-22 2005-10-27 Boehringer Ingelheim Pharmaceuticals, Inc. Method for the treatment of premenstrual and other female sexual disorders
WO2006096439A2 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
CA2608363A1 (en) * 2005-05-19 2006-11-23 Boehringer Ingelheim International Gmbh Method for the treatment of drug-induced sexual dysfunction
WO2006125041A1 (en) * 2005-05-19 2006-11-23 Boehringer Ingelheim International Gmbh Method for the treatment of sexual dysfunctions due to medical conditions
PL1912650T3 (pl) 2005-08-03 2018-01-31 Sprout Pharmaceuticals Inc Zastosowanie flibanseryny w leczeniu otyłości
CA2626134C (en) 2005-10-29 2013-12-24 Boehringer Ingelheim International Gmbh Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
US20070105869A1 (en) * 2005-11-08 2007-05-10 Stephane Pollentier Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
EP2037927B1 (en) * 2006-06-30 2010-01-27 Boehringer Ingelheim International GmbH Flibanserin for the treatment of urinary incontinence and related diseases
AR062320A1 (es) 2006-08-14 2008-10-29 Boehringer Ingelheim Int Formulaciones de flibanserina y metodo para fabricarlas
CL2007002214A1 (es) 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
WO2008022932A2 (en) 2006-08-25 2008-02-28 Boehringer Ingelheim International Gmbh Controlled release system and method for manufacturing the same
US8722682B2 (en) 2006-12-20 2014-05-13 Sprout Pharmaceuticals, Inc. Sulfated benzimidazolone derivatives having mixed serotonin receptor affinity
EP1955699A1 (en) * 2007-02-08 2008-08-13 Boehringer Ingelheim Pharma GmbH & Co. KG Use of flibanserin for the treatment of insomnia
CL2008002693A1 (es) 2007-09-12 2009-10-16 Boehringer Ingelheim Int Uso de flibanserina para el tratamiento de sintomas vasomotores seleccionados de sofocos, sudores nocturnos, cambios de estado de animo e irritabilidad
EP2090297A1 (en) * 2008-02-13 2009-08-19 Boehringer Ingelheim International GmbH Formulations of flibanserin
DE102008047910A1 (de) 2008-09-19 2010-03-25 Molkerei Meggle Wasserburg Gmbh & Co. Kg Tablettierhilfsstoff auf Laktose- und Cellulosebasis
US20120010216A1 (en) * 2010-07-06 2012-01-12 Brown Arthur M Pharmaceutical compositions containing vanoxerine
CN104926734B (zh) * 2015-07-07 2017-04-05 苏州立新制药有限公司 氟班色林的制备方法
WO2017128932A1 (zh) * 2016-01-31 2017-08-03 孟晓明 氟班色林的新晶型及其制备方法及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1251144B (it) * 1991-07-30 1995-05-04 Boehringer Ingelheim Italia Derivati del benzimidazolone
RS50742B (sr) * 2001-08-02 2010-08-31 Bidachem S.P.A. Stabilni polimorf flibanserina, postupak za njegovo dobijanje u industrijskim razmerama i njegova primena za pripremanje lekova
DE10138273A1 (de) * 2001-08-10 2003-02-27 Boehringer Ingelheim Pharma Arzneimittel mit neuroprotektiver Wirkung

Also Published As

Publication number Publication date
SI1511489T1 (sl) 2011-06-30
EP1511489A1 (en) 2005-03-09
AU2003240672A1 (en) 2003-12-02
CA2483597A1 (en) 2003-11-27
NZ537253A (en) 2007-09-28
CA2483597C (en) 2010-02-09
PL372457A1 (en) 2005-07-25
CN102240289A (zh) 2011-11-16
RS51718B (sr) 2011-10-31
PL211062B1 (pl) 2012-04-30
RS98704A (sr) 2006-12-15
JP2005530787A (ja) 2005-10-13
JP3919788B2 (ja) 2007-05-30
DK1511489T3 (da) 2011-05-02
EA007185B1 (ru) 2006-08-25
BR0311189A (pt) 2005-02-22
CN101002780A (zh) 2007-07-25
MXPA04011487A (es) 2005-02-14
DE60336225D1 (de) 2011-04-14
EP1511489B1 (en) 2011-03-02
ZA200408151B (en) 2006-06-28
NO329414B1 (no) 2010-10-18
KR20040111668A (ko) 2004-12-31
ATE499939T1 (de) 2011-03-15
HRP20041092B1 (hr) 2013-05-31
HRP20041092A2 (en) 2005-06-30
UA80135C2 (en) 2007-08-27
MEP55308A (en) 2011-05-10
IL164440A0 (en) 2005-12-18
ECSP045493A (es) 2005-03-10
CN1655789A (zh) 2005-08-17
NO20044547L (no) 2004-12-17
BRPI0311189B8 (pt) 2021-05-25
WO2003097058A1 (en) 2003-11-27
ES2361994T3 (es) 2011-06-27
BRPI0311189B1 (pt) 2019-04-09
EA200401515A1 (ru) 2005-06-30
KR101054237B1 (ko) 2011-08-08

Similar Documents

Publication Publication Date Title
CY1111470T1 (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α
UA96449C2 (en) Stable laquinimod preparations
BR0306870A (pt) Composição farmacêutica oral, e, método para preparar a mesma
TW200621737A (en) 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof
BR0015188A (pt) Composições farmacêuticas
NO20063429L (no) Brusende oral opiat doseringsform
UA84271C2 (en) Formate salt of o-desmethyl-venlafaxine
SE0301653D0 (sv) Novel compounds
ITMI20031570A1 (it) Composizione per uso dietetico, farmaceutico o cosmetico
UA93709C2 (ru) 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций
SE0302546D0 (sv) New compounds
TW200509992A (en) Dosage form containing pantoprazole as active ingredient
NO20062605L (no) Farmasoytisk formulering inneholdende smakssubstanser med forbedrede farmasoytiske egenskaper
TW200503785A (en) Dosage form containing (S)-pantoprazole as active ingredient
SE0200657D0 (sv) Novel Formulation
TNSN06012A1 (en) Emulsifying systems containing azetidine derivatives
NO20064808L (no) Orale matrixformuleringer med licarbazepin
TW200503783A (en) Oral pharmaceutical preparation for proton pump antagonists
MX2009008813A (es) Composicion farmaceutica que contiene floroglucinol y paracetamol.
EA200601015A1 (ru) Пероральные композиции дезоксипеганина и их применение
TNSN08242A1 (en) 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof
MXPA05007253A (es) Sales novedosas de derivados anticonvulsivantes.
TW200633717A (en) Process for and intermediates in the preparation of canfosfamide and its salts, pharmaceutical compositions containing some intermediates, and their use as anticancer agents
DK1399143T3 (da) Anvendelsen af Acetyl L-carnitin til fremstilling af et lægemiddel til behandling af anhedoni
DK1490049T3 (da) Citalopram til behandling af forhöjet blodtryk